FY2025 EPS Estimates for Hologic Raised by Leerink Partnrs

Hologic, Inc. (NASDAQ:HOLX) – Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Hologic in a research report issued on Wednesday, July 30th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will post earnings per share of $4.25 for the year, up from their prior forecast of $4.21. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic’s Q4 2025 earnings at $1.11 EPS, Q3 2026 earnings at $1.19 EPS, Q4 2026 earnings at $1.14 EPS and FY2026 earnings at $4.55 EPS.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the firm earned $1.06 EPS. The firm’s revenue was up 1.2% compared to the same quarter last year.

Several other analysts also recently commented on the stock. Stephens reduced their target price on shares of Hologic from $77.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, May 13th. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, May 27th. Royal Bank Of Canada reduced their price target on Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research note on Friday, May 2nd. Morgan Stanley increased their price objective on Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Evercore ISI boosted their target price on shares of Hologic from $62.00 to $68.00 and gave the company an “in-line” rating in a research report on Tuesday, July 8th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $76.42.

Hologic Price Performance

NASDAQ:HOLX opened at $67.16 on Friday. The company has a market cap of $14.97 billion, a P/E ratio of 27.87, a P/E/G ratio of 2.42 and a beta of 0.49. The firm’s fifty day moving average price is $64.42 and its two-hundred day moving average price is $62.81. Hologic has a one year low of $51.90 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.52.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director owned 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.88% of the company’s stock.

Hedge Funds Weigh In On Hologic

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. grew its stake in shares of Hologic by 34.4% during the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after buying an additional 1,692,177 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock valued at $412,159,000 after acquiring an additional 144,838 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after acquiring an additional 764,573 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Hologic by 1.6% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after acquiring an additional 69,878 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Hologic by 0.8% in the 1st quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock worth $216,973,000 after purchasing an additional 29,133 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.